{"pmid":32366695,"pmcid":"PMC7199903","title":"Site-specific glycan analysis of the SARS-CoV-2 spike.","text":["Site-specific glycan analysis of the SARS-CoV-2 spike.","The emergence of the betacoronavirus, SARS-CoV-2, the causative agent of COVID-19, represents a significant threat to global human health. Vaccine development is focused on the principal target of the humoral immune response, the spike (S) glycoprotein, which mediates cell entry and membrane fusion. SARS-CoV-2 S gene encodes 22 N-linked glycan sequons per protomer, which likely play a role in protein folding and immune evasion. Here, using a site-specific mass spectrometric approach, we reveal the glycan structures on a recombinant SARS-CoV-2 S immunogen. This analysis enables mapping of the glycan-processing states across the trimeric viral spike. We show how SARS-CoV-2 S glycans differ from typical host glycan processing, which may have implications in viral pathobiology and vaccine design.","Science","Watanabe, Yasunori","Allen, Joel D","Wrapp, Daniel","McLellan, Jason S","Crispin, Max","32366695"],"abstract":["The emergence of the betacoronavirus, SARS-CoV-2, the causative agent of COVID-19, represents a significant threat to global human health. Vaccine development is focused on the principal target of the humoral immune response, the spike (S) glycoprotein, which mediates cell entry and membrane fusion. SARS-CoV-2 S gene encodes 22 N-linked glycan sequons per protomer, which likely play a role in protein folding and immune evasion. Here, using a site-specific mass spectrometric approach, we reveal the glycan structures on a recombinant SARS-CoV-2 S immunogen. This analysis enables mapping of the glycan-processing states across the trimeric viral spike. We show how SARS-CoV-2 S glycans differ from typical host glycan processing, which may have implications in viral pathobiology and vaccine design."],"journal":"Science","authors":["Watanabe, Yasunori","Allen, Joel D","Wrapp, Daniel","McLellan, Jason S","Crispin, Max"],"date":"2020-05-06T11:00:00Z","year":2020,"_id":"32366695","source":"PubMed","week":"202019|May 04 - May 10","doi":"10.1126/science.abb9983","e_drugs":["Polysaccharides"],"topics":["Treatment","Mechanism"],"weight":1,"_version_":1666138496195100672,"score":9.490897,"similar":[{"pmid":32461612,"title":"Vulnerabilities in coronavirus glycan shields despite extensive glycosylation.","text":["Vulnerabilities in coronavirus glycan shields despite extensive glycosylation.","Severe acute respiratory syndrome (SARS) and Middle East respiratory syndrome (MERS) coronaviruses (CoVs) are zoonotic pathogens with high fatality rates and pandemic potential. Vaccine development focuses on the principal target of the neutralizing humoral immune response, the spike (S) glycoprotein. Coronavirus S proteins are extensively glycosylated, encoding around 66-87 N-linked glycosylation sites per trimeric spike. Here, we reveal a specific area of high glycan density on MERS S that results in the formation of oligomannose-type glycan clusters, which were absent on SARS and HKU1 CoVs. We provide a comparison of the global glycan density of coronavirus spikes with other viral proteins including HIV-1 envelope, Lassa virus glycoprotein complex, and influenza hemagglutinin, where glycosylation plays a known role in shielding immunogenic epitopes. Overall, our data reveal how organisation of glycosylation across class I viral fusion proteins influence not only individual glycan compositions but also the immunological pressure across the protein surface.","Nat Commun","Watanabe, Yasunori","Berndsen, Zachary T","Raghwani, Jayna","Seabright, Gemma E","Allen, Joel D","Pybus, Oliver G","McLellan, Jason S","Wilson, Ian A","Bowden, Thomas A","Ward, Andrew B","Crispin, Max","32461612"],"abstract":["Severe acute respiratory syndrome (SARS) and Middle East respiratory syndrome (MERS) coronaviruses (CoVs) are zoonotic pathogens with high fatality rates and pandemic potential. Vaccine development focuses on the principal target of the neutralizing humoral immune response, the spike (S) glycoprotein. Coronavirus S proteins are extensively glycosylated, encoding around 66-87 N-linked glycosylation sites per trimeric spike. Here, we reveal a specific area of high glycan density on MERS S that results in the formation of oligomannose-type glycan clusters, which were absent on SARS and HKU1 CoVs. We provide a comparison of the global glycan density of coronavirus spikes with other viral proteins including HIV-1 envelope, Lassa virus glycoprotein complex, and influenza hemagglutinin, where glycosylation plays a known role in shielding immunogenic epitopes. Overall, our data reveal how organisation of glycosylation across class I viral fusion proteins influence not only individual glycan compositions but also the immunological pressure across the protein surface."],"journal":"Nat Commun","authors":["Watanabe, Yasunori","Berndsen, Zachary T","Raghwani, Jayna","Seabright, Gemma E","Allen, Joel D","Pybus, Oliver G","McLellan, Jason S","Wilson, Ian A","Bowden, Thomas A","Ward, Andrew B","Crispin, Max"],"date":"2020-05-29T11:00:00Z","year":2020,"_id":"32461612","source":"PubMed","week":"202022|May 25 - May 31","doi":"10.1038/s41467-020-16567-0","locations":["glycan"],"e_drugs":["Polysaccharides","Nitrogen"],"topics":["Mechanism"],"weight":1,"_version_":1668079521525399553,"score":659.3602},{"pmid":32363391,"title":"Deducing the N- and O- glycosylation profile of the spike protein of novel coronavirus SARS-CoV-2.","text":["Deducing the N- and O- glycosylation profile of the spike protein of novel coronavirus SARS-CoV-2.","The current emergence of the novel coronavirus pandemic caused by SARS-CoV-2 demands the development of new therapeutic strategies to prevent rapid progress of mortalities. The coronavirus spike (S) protein, which facilitates viral attachment, entry and membrane fusion is heavily glycosylated and plays a critical role in the elicitation of the host immune response. The spike protein is comprised of two protein subunits (S1 and S2), which together possess 22 potential N-glycosylation sites. Herein, we report the glycosylation mapping on spike protein subunits S1 and S2 expressed on human cells through high resolution mass spectrometry. We have characterized the quantitative N-glycosylation profile on spike protein and interestingly, observed unexpected O-glycosylation modifications on the receptor binding domain (RBD) of spike protein subunit S1. Even though O-glycosylation has been predicted on the spike protein of SARS-CoV-2, this is the first report of experimental data for both the site of O-glycosylation and identity of the O-glycans attached on the subunit S1. Our data on the N- and O- glycosylation is strengthened by extensive manual interpretation of each glycopeptide spectra in addition to using bioinformatics tools to confirm the complexity of glycosylation in the spike protein. The elucidation of the glycan repertoire on the spike protein provides insights into the viral binding studies and more importantly, propels research towards the development of a suitable vaccine candidate.","Glycobiology","Shajahan, Asif","Supekar, Nitin T","Gleinich, Anne S","Azadi, Parastoo","32363391"],"abstract":["The current emergence of the novel coronavirus pandemic caused by SARS-CoV-2 demands the development of new therapeutic strategies to prevent rapid progress of mortalities. The coronavirus spike (S) protein, which facilitates viral attachment, entry and membrane fusion is heavily glycosylated and plays a critical role in the elicitation of the host immune response. The spike protein is comprised of two protein subunits (S1 and S2), which together possess 22 potential N-glycosylation sites. Herein, we report the glycosylation mapping on spike protein subunits S1 and S2 expressed on human cells through high resolution mass spectrometry. We have characterized the quantitative N-glycosylation profile on spike protein and interestingly, observed unexpected O-glycosylation modifications on the receptor binding domain (RBD) of spike protein subunit S1. Even though O-glycosylation has been predicted on the spike protein of SARS-CoV-2, this is the first report of experimental data for both the site of O-glycosylation and identity of the O-glycans attached on the subunit S1. Our data on the N- and O- glycosylation is strengthened by extensive manual interpretation of each glycopeptide spectra in addition to using bioinformatics tools to confirm the complexity of glycosylation in the spike protein. The elucidation of the glycan repertoire on the spike protein provides insights into the viral binding studies and more importantly, propels research towards the development of a suitable vaccine candidate."],"journal":"Glycobiology","authors":["Shajahan, Asif","Supekar, Nitin T","Gleinich, Anne S","Azadi, Parastoo"],"date":"2020-05-05T11:00:00Z","year":2020,"_id":"32363391","source":"PubMed","week":"202019|May 04 - May 10","doi":"10.1093/glycob/cwaa042","keywords":["covid-19","coronavirus vaccine","s1 s2 glycosylation","sars-cov-2 glycosylation","spike protein"],"e_drugs":["Nitrogen","Polysaccharides","Glycopeptides"],"topics":["Mechanism","Treatment"],"weight":1,"_version_":1666138496068222977,"score":459.54306},{"pmid":32422645,"title":"Cross-neutralization of SARS-CoV-2 by a human monoclonal SARS-CoV antibody.","text":["Cross-neutralization of SARS-CoV-2 by a human monoclonal SARS-CoV antibody.","SARS-CoV-2 is a newly emerged coronavirus responsible for the current COVID-19 pandemic that has resulted in more than 3.7 million infections and 260,000 deaths as of 6 May 2020(1,2). Vaccine and therapeutic discovery efforts are paramount to curb the pandemic spread of this zoonotic virus. The SARS-CoV-2 spike (S) glycoprotein promotes entry into host cells and is the main target of neutralizing antibodies. Here we describe multiple monoclonal antibodies targeting SARS-CoV-2 S identified from memory B cells of an individual who was infected with SARS-CoV in 2003. One antibody, named S309, potently neutralizes SARS-CoV-2 and SARS-CoV pseudoviruses as well as authentic SARS-CoV-2 by engaging the S receptor-binding domain. Using cryo-electron microscopy and binding assays, we show that S309 recognizes a glycan-containing epitope that is conserved within the sarbecovirus subgenus, without competing with receptor attachment. Antibody cocktails including S309 along with other antibodies identified here further enhanced SARS-CoV-2 neutralization and may limit the emergence of neutralization-escape mutants. These results pave the way for using S309- and S309-containing antibody cocktails for prophylaxis in individuals at high risk of exposure or as a post-exposure therapy to limit or treat severe disease.","Nature","Pinto, Dora","Park, Young-Jun","Beltramello, Martina","Walls, Alexandra C","Tortorici, M Alejandra","Bianchi, Siro","Jaconi, Stefano","Culap, Katja","Zatta, Fabrizia","De Marco, Anna","Peter, Alessia","Guarino, Barbara","Spreafico, Roberto","Cameroni, Elisabetta","Case, James Brett","Chen, Rita E","Havenar-Daughton, Colin","Snell, Gyorgy","Telenti, Amalio","Virgin, Herbert W","Lanzavecchia, Antonio","Diamond, Michael S","Fink, Katja","Veesler, David","Corti, Davide","32422645"],"abstract":["SARS-CoV-2 is a newly emerged coronavirus responsible for the current COVID-19 pandemic that has resulted in more than 3.7 million infections and 260,000 deaths as of 6 May 2020(1,2). Vaccine and therapeutic discovery efforts are paramount to curb the pandemic spread of this zoonotic virus. The SARS-CoV-2 spike (S) glycoprotein promotes entry into host cells and is the main target of neutralizing antibodies. Here we describe multiple monoclonal antibodies targeting SARS-CoV-2 S identified from memory B cells of an individual who was infected with SARS-CoV in 2003. One antibody, named S309, potently neutralizes SARS-CoV-2 and SARS-CoV pseudoviruses as well as authentic SARS-CoV-2 by engaging the S receptor-binding domain. Using cryo-electron microscopy and binding assays, we show that S309 recognizes a glycan-containing epitope that is conserved within the sarbecovirus subgenus, without competing with receptor attachment. Antibody cocktails including S309 along with other antibodies identified here further enhanced SARS-CoV-2 neutralization and may limit the emergence of neutralization-escape mutants. These results pave the way for using S309- and S309-containing antibody cocktails for prophylaxis in individuals at high risk of exposure or as a post-exposure therapy to limit or treat severe disease."],"journal":"Nature","authors":["Pinto, Dora","Park, Young-Jun","Beltramello, Martina","Walls, Alexandra C","Tortorici, M Alejandra","Bianchi, Siro","Jaconi, Stefano","Culap, Katja","Zatta, Fabrizia","De Marco, Anna","Peter, Alessia","Guarino, Barbara","Spreafico, Roberto","Cameroni, Elisabetta","Case, James Brett","Chen, Rita E","Havenar-Daughton, Colin","Snell, Gyorgy","Telenti, Amalio","Virgin, Herbert W","Lanzavecchia, Antonio","Diamond, Michael S","Fink, Katja","Veesler, David","Corti, Davide"],"date":"2020-05-19T11:00:00Z","year":2020,"_id":"32422645","source":"PubMed","week":"202021|May 18 - May 24","doi":"10.1038/s41586-020-2349-y","e_drugs":["Polysaccharides"],"topics":["Treatment","Mechanism"],"weight":1,"_version_":1667254896791912448,"score":287.61658},{"pmid":32155444,"pmcid":"PMC7102599","title":"Structure, Function, and Antigenicity of the SARS-CoV-2 Spike Glycoprotein.","text":["Structure, Function, and Antigenicity of the SARS-CoV-2 Spike Glycoprotein.","The emergence of SARS-CoV-2 has resulted in >90,000 infections and >3,000 deaths. Coronavirus spike (S) glycoproteins promote entry into cells and are the main target of antibodies. We show that SARS-CoV-2 S uses ACE2 to enter cells and that the receptor-binding domains of SARS-CoV-2 S and SARS-CoV S bind with similar affinities to human ACE2, correlating with the efficient spread of SARS-CoV-2 among humans. We found that the SARS-CoV-2 S glycoprotein harbors a furin cleavage site at the boundary between the S1/S2 subunits, which is processed during biogenesis and sets this virus apart from SARS-CoV and SARS-related CoVs. We determined cryo-EM structures of the SARS-CoV-2 S ectodomain trimer, providing a blueprint for the design of vaccines and inhibitors of viral entry. Finally, we demonstrate that SARS-CoV S murine polyclonal antibodies potently inhibited SARS-CoV-2 S mediated entry into cells, indicating that cross-neutralizing antibodies targeting conserved S epitopes can be elicited upon vaccination.","Cell","Walls, Alexandra C","Park, Young-Jun","Tortorici, M Alejandra","Wall, Abigail","McGuire, Andrew T","Veesler, David","32155444"],"abstract":["The emergence of SARS-CoV-2 has resulted in >90,000 infections and >3,000 deaths. Coronavirus spike (S) glycoproteins promote entry into cells and are the main target of antibodies. We show that SARS-CoV-2 S uses ACE2 to enter cells and that the receptor-binding domains of SARS-CoV-2 S and SARS-CoV S bind with similar affinities to human ACE2, correlating with the efficient spread of SARS-CoV-2 among humans. We found that the SARS-CoV-2 S glycoprotein harbors a furin cleavage site at the boundary between the S1/S2 subunits, which is processed during biogenesis and sets this virus apart from SARS-CoV and SARS-related CoVs. We determined cryo-EM structures of the SARS-CoV-2 S ectodomain trimer, providing a blueprint for the design of vaccines and inhibitors of viral entry. Finally, we demonstrate that SARS-CoV S murine polyclonal antibodies potently inhibited SARS-CoV-2 S mediated entry into cells, indicating that cross-neutralizing antibodies targeting conserved S epitopes can be elicited upon vaccination."],"journal":"Cell","authors":["Walls, Alexandra C","Park, Young-Jun","Tortorici, M Alejandra","Wall, Abigail","McGuire, Andrew T","Veesler, David"],"date":"2020-03-11T11:00:00Z","year":2020,"_id":"32155444","source":"PubMed","week":"202011|Mar 09 - Mar 15","doi":"10.1016/j.cell.2020.02.058","keywords":["sars-cov","sars-cov-2","antibodies","coronavirus","cryo-em","neutralizing antibodies","spike glycoprotein","viral receptor"],"topics":["Mechanism","Treatment"],"weight":1,"_version_":1666138490664910848,"score":278.78946},{"pmid":32374457,"title":"The anti-HIV Drug Nelfinavir Mesylate (Viracept) is a Potent Inhibitor of Cell Fusion Caused by the SARS-CoV-2 Spike (S) Glycoprotein Warranting further Evaluation as an Antiviral against COVID-19 infections.","text":["The anti-HIV Drug Nelfinavir Mesylate (Viracept) is a Potent Inhibitor of Cell Fusion Caused by the SARS-CoV-2 Spike (S) Glycoprotein Warranting further Evaluation as an Antiviral against COVID-19 infections.","SARS coronavirus-2 (SARS CoV-2) is the causative agent of the Coronavirus Disease-2019 (COVID-19) pandemic. Coronaviruses enter cells via fusion of the viral envelope with the plasma membrane and/or via fusion of the viral envelope with endosomal membranes after virion endocytosis. The Spike (S) glycoprotein is a major determinant of virus infectivity. Herein, we show that transient expression of the SARS CoV-2 S glycoprotein in Vero cells caused extensive cell fusion (formation of syncytia) in comparison to limited cell fusion caused by the SARS CoV S glycoprotein. Both S glycoproteins were detected intracellularly and on transfected Vero cell surfaces. These results are in agreement with published pathology observations of extensive syncytial formation in lung tissues of COVID-19 patients. These results suggest that SARS CoV-2 is able to spread from cell-to-cell much more efficiently than SARS-CoV effectively avoiding extracellular neutralizing antibodies. A systematic screening of several drugs including cardiac glycosides and kinase inhibitors and inhibitors of HIV entry revealed that only the FDA approved HIV-protease inhibitor, nelfinavir mesylate (Viracept) drastically inhibited Sn and So-mediated cell fusion with complete inhibition at a 10 muM concentration. In silico docking experiments suggested the possibility that nelfinavir may bind inside the S trimer structure, proximal to the S2 amino terminus directly inhibiting Sn and So-mediated membrane fusion. Also, it is possible that nelfinavir may act to inhibit S proteolytic processing within cells. These results warrant further investigations of the potential of nelfinavir mesylate to inhibit virus spread at early times after SARS CoV-2 symptoms appear. This article is protected by copyright. All rights reserved.","J Med Virol","Musarrat, Farhana","Chouljenko, Vladimir","Dahal, Achyut","Nabi, Rafiq","Chouljenko, Tamara","Jois, Seetharama D","Kousoulas, Konstantin G","32374457"],"abstract":["SARS coronavirus-2 (SARS CoV-2) is the causative agent of the Coronavirus Disease-2019 (COVID-19) pandemic. Coronaviruses enter cells via fusion of the viral envelope with the plasma membrane and/or via fusion of the viral envelope with endosomal membranes after virion endocytosis. The Spike (S) glycoprotein is a major determinant of virus infectivity. Herein, we show that transient expression of the SARS CoV-2 S glycoprotein in Vero cells caused extensive cell fusion (formation of syncytia) in comparison to limited cell fusion caused by the SARS CoV S glycoprotein. Both S glycoproteins were detected intracellularly and on transfected Vero cell surfaces. These results are in agreement with published pathology observations of extensive syncytial formation in lung tissues of COVID-19 patients. These results suggest that SARS CoV-2 is able to spread from cell-to-cell much more efficiently than SARS-CoV effectively avoiding extracellular neutralizing antibodies. A systematic screening of several drugs including cardiac glycosides and kinase inhibitors and inhibitors of HIV entry revealed that only the FDA approved HIV-protease inhibitor, nelfinavir mesylate (Viracept) drastically inhibited Sn and So-mediated cell fusion with complete inhibition at a 10 muM concentration. In silico docking experiments suggested the possibility that nelfinavir may bind inside the S trimer structure, proximal to the S2 amino terminus directly inhibiting Sn and So-mediated membrane fusion. Also, it is possible that nelfinavir may act to inhibit S proteolytic processing within cells. These results warrant further investigations of the potential of nelfinavir mesylate to inhibit virus spread at early times after SARS CoV-2 symptoms appear. This article is protected by copyright. All rights reserved."],"journal":"J Med Virol","authors":["Musarrat, Farhana","Chouljenko, Vladimir","Dahal, Achyut","Nabi, Rafiq","Chouljenko, Tamara","Jois, Seetharama D","Kousoulas, Konstantin G"],"date":"2020-05-07T11:00:00Z","year":2020,"_id":"32374457","source":"PubMed","week":"202019|May 04 - May 10","doi":"10.1002/jmv.25985","keywords":["antiviral agents","cell fusion","cellular effect","coronavirus","entry inhibitors","fusion protein","glycoproteins","infection","sars coronavirus","virus classification"],"e_drugs":["Tin","Nelfinavir"],"topics":["Treatment","Mechanism"],"weight":1,"_version_":1666138496346095616,"score":263.80927}]}